Appendix 4E and FY26 financial reports

• Total revenue down 0.7% to $735.8m
• Underlying profit up 4.6% to $35.2m
• Dividend increased to 9.25 cents per share

Australian Clinical Labs (ACL) reported its FY26 financial results, showing a slight decline in total revenue by 0.7% to $735.8 million. However, underlying profit increased by 4.6% to $35.2 million. Statutory profit decreased by 26.9% to $23.7 million, while underlying earnings per share rose by 8.5% to 18.33 cents. The company declared a final dividend of 9.25 cents per share, fully franked, up from 9.00 cents in the previous year. The company also released its Appendix 4E and FY26 financial reports, providing comprehensive details of its financial performance.

FY26 total revenue: $735.8m, underlying profit: $35.2m, earnings per share: 18.33c

ACL anticipates continued growth in underlying profit and earnings per share in the coming years.